CSL Behring's hemophilia B gene therapy, Hemgenix, carries a $3.5 million list price. But the company contends that by reducing economic burdens associated with bleeding and prophylactic infusions, the one-time treatment will save money over time.
BrightInsight developed the Disease Management Solution to help biopharma and medtech companies bring their Software as a Medical Device (SaMD) to market faster, according to BrightInsight CEO and Co-founder Dr. Kal Patel.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The therapy, etranacogene dezaparvovec, is currently in Phase III clinical development for hemophilia B. Shares of uniQure were down nearly 20%, but an investment bank analyst wrote that the financial terms were favorable for the company.
A drug therapy for hemophilia patients developed by CSL Behring has been given orphan drug status by U.S. regulators. The hemophilia therapeutic from CSL Behring, a plasma protein therapeutics producer in King of Prussia, Pennsylvania, links recombinant fusion protein coagulation factor VIIa with albumin. The treatment is designed to help hemophilia A and hemophilia B […]